2505 Meridian Pkwy #340
Durham, NC, 27713 United States
Russell 2000 (June 2015)
All that shimmers isn't . . . enhanced by lipid conjugate technology. Chimerix has developed technology to make molecules with therapeutic potential into oral drugs. Its lipid conjugate technology can modify drug compounds to mimic a particular lipid metabolite that is absorbed by the small intestine, thus protecting the compounds from being broken down in the stomach. Chimerix is using its technology to develop lead drug candidate CMX001 (brincidofovir) to fight smallpox infections or bad reactions to smallpox vaccinations. The development-stage firm is also targeting drug-resistant HIV and hepatitis B with its clinical stage CMX157 nucleotide analog. The company went public in 2013.